A 4-Part Parallel Group, Randomized, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Repeat Doses of GSK1018921 in Healthy Volunteers and Stable Patients With Schizophrenia and to Evaluate Its Effects on Pharmacokinetics of Midazolam.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs GSK 1018921; Midazolam
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- 11 Jul 2009 New trial record